Skip to content

Drug interactions

Fingolimod + Liposomal doxorubicin

Severity: Major

Fingolimod and Liposomal doxorubicin: major interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Both agents suppress immune function, so combined use may increase the risk of serious infections. Fingolimod lowers circulating lymphocytes, adding to chemotherapy-related myelosuppression.

What this interaction means in plain words

Fingolimod and Liposomal doxorubicin can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Fingolimod belongs to Central Nervous System; Liposomal doxorubicin belongs to Oncology.

Evidence level: Low

Why it happens

Additive immunosuppression from lymphocyte sequestration by fingolimod and myelosuppression by doxorubicin.

What to do

Avoid concurrent use where possible and monitor blood counts and signs of infection. Consider interrupting fingolimod during chemotherapy.

What to ask your pharmacist

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Fingolimod and Liposomal doxorubicin, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Fingolimod with Liposomal doxorubicin?

MediHelp rates the interaction as major. Fingolimod and Liposomal doxorubicin can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Both agents suppress immune function, so combined use may increase the risk of serious infections. Fingolimod lowers circulating lymphocytes, adding to chemotherapy-related myelosuppression.

How serious is the interaction between Fingolimod and Liposomal doxorubicin?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid concurrent use where possible and monitor blood counts and signs of infection. Consider interrupting fingolimod during chemotherapy.

What other medicines interact with Liposomal doxorubicin?

MediHelp also lists interactions of Liposomal doxorubicin with, for example, Dengue vaccine, Belatacept, Cyclosporine. The full list is on the Liposomal doxorubicin page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in